FIELD: medicine.
SUBSTANCE: invention refers to medical industry and concerns production of a live influenza xa vaccine. The method for improving immunogenicity of the cold-adapted influenza vaccine is characterised by the fact that the vaccine is added by an adjuvant presented by chitosonium glutamate of final concentration 0.5% having a degree of deacetylation within 66-99% and molecular weight within 70-500 kDa.
EFFECT: method is easy to implement and enables effectively improving immunogenicity of the cold-adapted influenza vaccine.
5 tbl, 5 ex
Authors
Dates
2012-10-27—Published
2010-04-14—Filed